4/19
04:20 am
gsk
GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve [Seeking Alpha]
Low
Report
GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve [Seeking Alpha]
3/24
04:13 pm
gsk
12 Best Biotech Penny Stocks to Invest In [Yahoo! Finance]
Low
Report
12 Best Biotech Penny Stocks to Invest In [Yahoo! Finance]
3/16
08:00 am
gsk
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
Low
Report
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
3/7
12:00 pm
gsk
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
Low
Report
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
3/4
08:06 am
gsk
GSK plc (NYSE: GSK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
Low
Report
GSK plc (NYSE: GSK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
2/15
02:56 am
gsk
GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy [Seeking Alpha]
Low
Report
GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy [Seeking Alpha]
2/14
08:00 am
gsk
GSK Exercises Option to License Elsie Biotechnologies’ Discovery Platform to Find and Develop Novel Oligonucleotides
Low
Report
GSK Exercises Option to License Elsie Biotechnologies’ Discovery Platform to Find and Develop Novel Oligonucleotides
2/13
07:00 am
gsk
GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
Low
Report
GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
2/6
07:00 am
gsk
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
Low
Report
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk